Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test how well the drug works, safety and tolerability of an
investigational drug called Ruxolitinib in gliomas and glioblastomas, when combined with
standard treatment for brain cancer, temozolomide and radiation.
Ruxolitinib is an experimental drug that works by targeting proteins in cells and stops them
from growing. Ruxolitinib is experimental because it is not approved by the Food and Drug
Administration (FDA) for the treatment of gliomas or glioblastomas
Temozolomide works by damaging the DNA of tumor cells so that they cannot divide properly.
Some tumor cells can repair that damage and therefore be resistant to temozolomide.